Back to Agenda
Beyond the Frequentist Approach in Hard to Recruit Populations: Acceptance of Bayesian Methods for Registration/Pivotal Trial
Session Chair(s)
Philip Hougaard, DRSC, PHD
Vice President, Biostatistics and Data Science
Lundbeck A/S, Denmark
Alternative methods to a frequentist approach, such as Bayesian, may be superior in certain situations; particularly, when analyzing trial data to support approvals in small populations. Regulators are increasingly considering novel methods.
Learning Objective : Examine global considerations for leveraging Bayesian approaches in pivotal trials to support marketing authorization; State and debate the situations and circumstances where the Bayesian approach may be the most appropriate method of analysis; Discuss health authority considerations that could facilitate the use of alternative analytical methods beyond the frequentist approach; Identify ways to bridge existing gaps in applying Bayesian methods in clinical research.
Speaker(s)
FDA perspective
Yun Wang, PHD
FDA, United States
Deputy Division Director, CDER/OTS/OB
EMA Perspective
Andrew Thomson, PHD, MA, MS
European Medicines Agency, Netherlands
Statistician, Methodology Taskforce
Industry Perspective
Scott Berry, PHD
Berry Consultants LLC, United States
President and Senior Statistical Scientist
Have an account?